Kiromic Biopharma, Inc. is a clinical stage biotherapeutics company, which engages in DIAMOND AI and discovers, validates, and develops cell and gene therapies with a therapeutic focus on immuno-oncology. The company is headquartered in Houston, Texas and currently employs 44 full-time employees. The company went IPO on 2020-10-16. The firm is engaged in developing an allogeneic Gamma Delta T-cell therapy featuring proprietary end-to-end bioinformatic, artificial intelligence (AI) targeting and manufacturing technologies to address solid tumors. The company has five clinical programs to study its key product candidates: Deltacel-01, Alexis-ISO-1, Alexis-PRO-1, Isocel combination, and Procel combination. Deltacel is its first allogeneic, off-the-shelf GDT cell-based product in Phase I clinical-stage. Its Procel and Isocel product candidates consist of allogeneic, engineered, off-the-shelf GDT cells, and they are in the preclinical development stage. Its Isocel product candidate consists of engineered GDTs that target Mesothelin Isoform 2, a target that has been discovered and prioritized using its Diamond AI bio-informatic platform. Its Procel product candidate consists of engineered GDTs that target PD-L1.

Industry: Biological Products, (No Diagnostic Substances) Peers: Fresh Tracks Therapeutics, Inc. POLARITYTE, INC. Creative Medical Technology Holdings Inc NUTRA PHARMA CORP LadRx Corp MANHATTAN SCIENTIFICS INC Revelation Biosciences Inc Scopus BioPharma Inc.